This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
ELSEWHERE in these pages is the final report of a pioneer effort in the pooling of clinical data from a cross-section of investigators in the United States and Canada, the intent of which was to replace confusion with some degree of clarity in a "new" area of cancer therapeusis. Although the use of estrogenic and androgenic hormones for palliation of mammary carcinoma is no longer new, as it was when the Committee on Research initiated this study in 1946, some of the prejudices and mistaken practices current then seem to be almost as prevalent now. The primary benefit of a cooperative study should be an accumulation of comparable data, on samples of significant size, long before the individual investigator or institution can acquire the experience necessary for valid reporting. The Subcommittee on Breast and Genital Cancer, which is responsible for this study, has published various reports; however, the final evaluation
Macdonald I. SEX STEROIDS FOR PALLIATION OF DISSEMINATED MAMMARY CARCINOMAGUEST EDITORIAL. JAMA. 1960;172(12):1288–1289. doi:10.1001/jama.1960.03020120066012